Royal Fund Management’s Editas Medicine EDIT Stock Holding History

Royal Fund Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25	Closed	–	–	256
2020 Q1	$0	Hold	25	–	–	﹤0.01%	597
2019 Q4	$0	Hold	25	–	–	﹤0.01%	640
2019 Q3	$0	Hold	25	–	–	﹤0.01%	594
2019 Q2	$0	Hold	25	–	–	﹤0.01%	566
2019 Q1	$0	Hold	25	–	–	﹤0.01%	601
2018 Q4	$0	Hold	25	–	–	﹤0.01%	595
2018 Q3	$0	Buy	+25	New	+$808	﹤0.01%	545

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royal Fund Management's EDIT Position: Q2 2020 in Review

Royal Fund Management sold out of Editas Medicine (EDIT) in Q2 2020, closing a stake of 25 shares.

Royal Fund Management first reported a position in EDIT in Q3 2018 and held it in 7 quarters. The position peaked at $0 in Q1 2020. 238 funds tracked by Wall St. Rank hold EDIT as of Q2 2020.

Royal Fund Management reported no remaining Editas Medicine position as of Q2 2020 after selling out during the quarter.
Royal Fund Management sold 25 Editas Medicine shares in Q2 2020.
Royal Fund Management first reported a position in Editas Medicine in Q3 2018 and held it in 7 quarters.
Royal Fund Management's Editas Medicine position peaked at $0 in Q1 2020.
238 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.